At the 50% enrollment analysis, the proportion of patients with HbA 1c above 7% did not differ between groups
Trends in first-time prescribing First-time prescribing rates (first-time GLP-1 RA prescriptions per total prescriptions) in September 2025 are slightly decreased compared to June 2025 (-12.5%)
Off-Label Use: Some medications are prescribed off-label for weight loss: Semaglutide (Ozempic): FDA-approved for type 2 diabetes (not weight loss) Identical to Wegovy but different indication Commonly prescribed off-label for weight loss Same effectiveness as Wegovy Tirzepatide (Mounjaro): FDA-approved for type 2 diabetes (not weight loss) Identical to Zepbound but different indication Prescribed off-label for weight loss before Zepbound approval Same effectiveness as Zepbound Metformin: Diabetes medication sometimes used for weight loss Produces only 1-3% weight loss Not FDA-approved for weight loss Generally not recommended as primary weight loss medication The Current State of Weight Loss Medication: Clear Winners: GLP-1 receptor agonists (especially tirzepatide and semaglutide) have become the gold standard for medical weight loss, producing results previously unattainable with medication alone
Constipation or diarrhea: Changes in digestion can temporarily affect bowel habits
High treatment costs have fueled a growing grey market of compounded semaglutide products, raising concerns among regulators over quality, consistency, and patient safety
Having severe overweight or obesity is not only about body weight but about health
:max_bytes(150000):strip_icc()/Health-GettyImages-PharmacistsGLP1s-091528aad5314e0f94e92880dee97289.jpg)
